Researchers recently investigated the efficacy of low-dose infliximab CNS tuberculosis treatment in patients with severe inflammatory complications. This retrospective cohort study focused on 20 patients suffering from severe central nervous system (CNS) tuberculosis (TB). Traditionally, CNS TB leads to high morbidity and mortality despite standard antitubercular therapy. Therefore, clinicians are exploring adjunctive therapies to manage persistent inflammation effectively.

Clinical Results of Low-Dose Infliximab CNS Tuberculosis

The study utilized a standardized regimen of 5 mg/kg of infliximab as an adjunctive therapy. At the three-month follow-up, 60% of the participants achieved disability-free survival. This was defined as a modified Rankin Scale score of 2 or less. Furthermore, 75% of the patients exhibited clinically meaningful improvements in their neurological status. These results are significant because they match the success rates typically associated with higher-dose regimens. Consequently, low-dose infliximab may offer a safer and more cost-effective alternative for patients in high-burden settings like India.

Despite these positive results, the researchers emphasized the need for randomized controlled trials. These trials will help optimize dosing schedules and confirm long-term safety profiles. Moreover, adjunctive infliximab appears particularly useful for patients experiencing paradoxical reactions. Such reactions often cause neurological deterioration even when antitubercular drugs are working. Thus, this treatment could provide a critical safety net for severe cases.

How effective is low-dose infliximab for CNS TB?

About 60% of patients achieved disability-free survival at three months. This shows similar efficacy to higher-dose treatments according to recent cohort data.

What is the recommended dose evaluated in this study?

The study specifically evaluated a low-dose regimen of 5 mg/kg administered intravenously as an adjunctive therapy.

Why is infliximab used in CNS tuberculosis management?

It targets TNF-alpha to reduce severe brain inflammation and paradoxical reactions that standard antitubercular treatments cannot always control.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Kumar D SS et al. Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort Study. Clin Infect Dis. 2026 Mar 20. doi: undefined. PMID: 41856917.

Manesh A, Gautam P, Kumar D SS, et al. Effectiveness of adjunctive high-dose infliximab therapy to improve disability-free survival among patients with severe central nervous system tuberculosis: a matched retrospective cohort study. Clin Infect Dis. 2023 Nov 17;77(10):1460-1467.

Benhard J, Monsel G, et al. Standardized Infliximab Regimen to Treat Severe Central Nervous System Tuberculosis: A Case Series of 18 Patients. Open Forum Infect Dis. 2025 Aug 12;12(8):ofae432.